Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04684147Phase 2Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inaticabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Juventas Cell Therapy Ltd. Primary endpoint: Overall Remission Rate at 3 months. Started Dec 2020; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04684147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684147.